Prevymis 240mg (Letermovir Tablet) 240mg

Prevymis 240mg (Letermovir) is an antiviral tablet used to prevent cytomegalovirus (CMV) infection in certain high-risk patients. This medication helps reduce the risk of CMV disease after organ or stem cell transplants. Store at room temperature and keep out of reach of children.

Strength

240mg

Pack Size

28s

Storage

Ambient

Manufacturer / TM Owner

MSD Sharp & Dohme

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Prevymis 240mg is primarily used to prevent cytomegalovirus (CMV) infection in adults who have undergone a hematopoietic stem cell transplant and are at high risk for CMV. It may also be prescribed for other transplant patients as determined by a healthcare provider. This medication works by inhibiting viral replication, helping to reduce the likelihood of CMV-related complications.

Side Effects

Prevymis 240mg helps manage the risk of CMV infection by slowing the growth of the virus in the body. Patients may experience improved immune response and reduced symptoms associated with CMV reactivation. Common effects include gastrointestinal discomfort or mild headache, though these are not guaranteed.

Precautions & Warnings

Keep Prevymis 240mg in its original packaging at room temperature, away from moisture and direct sunlight. Do not use if the packaging is damaged or the tablets show signs of tampering. Inform your healthcare provider about all medications and supplements you are taking before starting this treatment.

Avoid Interactions

Prevymis 240mg may interact with certain medications, including CYP3A inhibitors or inducers, which can affect its effectiveness or increase side effects. Avoid grapefruit products while taking this medication, as they may alter drug levels in the blood. Always consult a healthcare professional before combining with other drugs.

Frequently Asked Questions

Prevymis 240mg is used to prevent cytomegalovirus (CMV) infection in high-risk transplant patients.

Store Prevymis 240mg at room temperature in its original packaging, away from moisture and children.

Consult your healthcare provider before combining Prevymis with other drugs, as interactions may occur.

Common effects may include mild headache or gastrointestinal discomfort, but these vary by individual.

No, Prevymis 240mg requires a prescription from a healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.